At the core of AWvi lies a rigorous, science-driven method. Every formula undergoes independent clinical trials designed to validate real, measurable results.
The results and scientific robustness of these clinical studies led to the granting of a patent (EP4151217) and the publication of peer-reviewed articles, further reinforcing the innovative nature and scientific credibility of AWvi’s solutions.
This has also contributed to their growing adoption by the professional community, including practitioners, aesthetic doctors and skin health experts.
The In & Out approach demonstrates a synergistic effect, improving measured biophysical parameters by an average of 2.1 times compared with the supplement or topical solutions used alone.
The study has been designed — in the current framework proposed by Commission Regulation (EU) No 655/2013 — to assess the all-encompassing effectiveness of the AWvi range in addressing multiple benefits related to skin aging and skin health.
In particular, the study aims to assess the effectiveness of AWvi’s solutions, while also exploring the synergistic impact of using The Skin Biotic nutraceutical in combination with the three cosmeceutical (topical) solutions.
Clinical study protocol:
Multicentric, double-blind, randomized, placebo-controlled study.
96 healthy subjects, divided into 4 groups of 24 subjects each, enrolled by a board-certified dermatologist, according to specific inclusion and exclusion criteria:
– Group 1: 24 subjects are treated with The Skin Biotic + Placebo topical solutions
– Group 2: 24 subjects are treated with Placebo supplement + Placebo topical solutions
– Group 3: 24 subjects are treated with The Skin Biotic + AWvi topical solutions
– Group 4: 24 subjects are treated with Placebo supplement + AWvi topical solutions
Main inclusion criteria: Age range: 45 to 65 years, with an average age of 55 years; Including sensitive skin; Skin ageing from mild to moderate.
8 weeks study duration; Assessment of the product effects after 4- and 8-week use.
AWvi substantiated the dermatological tolerance of its topical solutions through 48-hour closed human patch tests under occlusion, conducted on 25 volunteers to assess potential skin irritation.
Based on the Mean Irritation Index (IIM), according to the amended Draize classification, all three tested products recorded exceptionally low scores ranging from 0.00 to 0.32.
These results support their dermatological tolerance and indicate that The Gentle Cleanser, The Power Serum and The Active Cream are suitable for sensitive skin.
AWvi’s vision is grounded in scientific discoveries that have reshaped the understanding of health, skin biology and the microbiome.
In a category often driven by broad claims, AWvi distinguishes itself by focusing on ingredients and mechanisms whose relevance is supported by clinical and peer-reviewed evidence, rather than by marketing terminology alone.
Not every probiotic, microbiome-related ingredient or delivery technology can be assumed to provide a defined benefit: efficacy depends on the specific strain, biological target, dosage, formulation and clinical context
This is why AWvi goes beyond traditional cosmetic narratives, developing solutions anchored in true clinical science, designed to work with the body’s own biological functions and deliver innovative, measurable benefits.
